NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

In the EU Clinical Trial register, it shows that the primary endpoint for the DCVax-L trial is Overall Survival (OS), not PFS (see Section E.2.1 and E.2.2).

Also, the clinical trial register says that OS primary endpoint will be evaluated in October 2020 (see Section E.5.1.1).

In Section E.5.2, it says that the "second secondary" endpoint is PFS. It also says that the second secondary endpoint will be evaluated in October 2020:

https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001977-13/GB#summary